Comparing Personalized Lower-Dose Versus Standard Radiation Therapy with Chemotherapy in Adults with HPV-Positive Throat Cancer

What this Trial Is About

Researchers are evaluating whether a personalized approach to chemoradiation therapy, which may involve a lower radiation dose, is as effective as the standard chemoradiation therapy in adults with HPV-positive throat cancer. The study also aims to determine if the lower radiation dose combined with standard chemotherapy causes fewer side effects and how both approaches affect participants quality of life, measured through questionnaires. Participants will be randomly assigned to one of two groups a personalized chemoradiation therapy group or a standard chemoradiation therapy group. The personalized group will receive radiation doses based on hypoxia status, with hypoxia-negative patients receiving 30 Gy in 15 fractions and hypoxia-positive patients receiving 70 Gy total dose the standard group receives 70 Gy regardless of hypoxia status. Both groups receive concurrent chemotherapy as per guidelines. An FMISO-PET scan is performed during treatment to assess hypoxia, and a post-treatment FDG PETCT scan is done about four months after therapy to evaluate disease status. During the study, participants fill out quality of life questionnaires and undergo imaging and laboratory assessments. Researchers monitor overall survival over two years as the primary outcome. If persistent disease is detected after treatment, standard neck dissection and further care are offered based on pathology. The study lasts until August 2027, with ongoing assessments of treatment effects and side effects throughout participation.

A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer